- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Mereo BioPharma Group PLC ADR is a biotechnology business based in the US. Mereo BioPharma Group PLC ADR shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.35 – a decrease of 10.43% over the previous week. Mereo BioPharma Group PLC ADR employs 33 staff and has a trailing 12-month revenue of around $1 million.
What's in this guide?
Our top picks for where to buy Mereo BioPharma Group PLC ADR stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Mereo BioPharma Group PLC ADR stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MREO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Mereo BioPharma Group PLC ADR stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Mereo BioPharma Group PLC ADR stock price (NASDAQ: MREO)
Use our graph to track the performance of MREO stocks over time.Mereo BioPharma Group PLC ADR shares at a glance
Information last updated 2024-12-15.
| Latest market close | $3.35 |
|---|---|
| 52-week range | $2.03 - $5.02 |
| 50-day moving average | $4.29 |
| 200-day moving average | $3.76 |
| Wall St. target price | $7.22 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.25 |
Is it a good time to buy Mereo BioPharma Group PLC ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Mereo BioPharma Group PLC ADR price performance over time
Historical closes compared with the close of $3.29 from 2024-12-19
| 1 week (2024-12-13) | -12.03% |
|---|---|
| 1 month (2024-11-22) | -11.56% |
| 3 months (2024-09-20) | -22.59% |
| 6 months (2024-06-21) | -17.34% |
| 1 year (2023-12-21) | 60.49% |
|---|---|
| 2 years (2022-12-21) | 481.27% |
| 3 years (2021-12-21) | 99.39% |
| 5 years (2019-12-20) | 159.46% |
Mereo BioPharma Group PLC ADR financials
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $936,000 |
| Return on assets TTM | -23.86% |
| Return on equity TTM | -48.47% |
| Profit margin | 0% |
| Book value | $0.51 |
| Market Capitalization | $630.8 million |
TTM: trailing 12 months
Mereo BioPharma Group PLC ADR share dividends
We're not expecting Mereo BioPharma Group PLC ADR to pay a dividend over the next 12 months.
Mereo BioPharma Group PLC ADR share price volatility
Over the last 12 months, Mereo BioPharma Group PLC ADR's shares have ranged in value from as little as $2.03 up to $5.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group PLC ADR's is 0.97. This would suggest that Mereo BioPharma Group PLC ADR's shares are less volatile than average (for this exchange).
Mereo BioPharma Group PLC ADR overview
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Frequently asked questions
What percentage of Mereo BioPharma Group PLC ADR is owned by insiders or institutions?Currently 1.025% of Mereo BioPharma Group PLC ADR shares are held by insiders and 65.668% by institutions. How many people work for Mereo BioPharma Group PLC ADR?
Latest data suggests 33 work at Mereo BioPharma Group PLC ADR. When does the fiscal year end for Mereo BioPharma Group PLC ADR?
Mereo BioPharma Group PLC ADR's fiscal year ends in December. Where is Mereo BioPharma Group PLC ADR based?
Mereo BioPharma Group PLC ADR's address is: One Cavendish Place, London, United Kingdom, W1G 0QF What is Mereo BioPharma Group PLC ADR's ISIN number?
Mereo BioPharma Group PLC ADR's international securities identification number is: US5894921072 What is Mereo BioPharma Group PLC ADR's CUSIP number?
Mereo BioPharma Group PLC ADR's Committee on Uniform Securities Identification Procedures number is: 589492107
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question